What is the ROE (Return on Equity) of Neuronetics this year?
The ROE of Neuronetics this year is -0.88 undefined.
Neuronetics ROE 2024
Neuronetics ROE
-0.88
Neuronetics Dividend yield
Ticker
STIM
ISIN
US64131A1051
WKN
A2JPMY
In 2024, Neuronetics's return on equity (ROE) was -0.88, a 35.68% increase from the -0.65 ROE in the previous year.
Neuronetics Aktienanalyse
What does Neuronetics do?
Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Neuronetics's Return on Equity (ROE)
Neuronetics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Neuronetics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Neuronetics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Neuronetics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Neuronetics Stock
How has the Return on Equity (ROE) of Neuronetics developed compared to the previous year?
The ROE of Neuronetics has increased by 35.68% increased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Neuronetics?
A high ROE indicates that Neuronetics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Neuronetics?
A low ROE can indicate that Neuronetics is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Neuronetics affect the company?
A change in ROE (Return on Equity) of Neuronetics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Neuronetics?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Neuronetics?
Some factors that can influence Neuronetics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Neuronetics pay?
Over the past 12 months, Neuronetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neuronetics is expected to pay a dividend of 0 USD.
What is the dividend yield of Neuronetics?
The current dividend yield of Neuronetics is .
When does Neuronetics pay dividends?
Neuronetics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neuronetics?
Neuronetics paid dividends every year for the past 0 years.
What is the dividend of Neuronetics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neuronetics located?
Neuronetics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neuronetics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neuronetics from 5/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/27/2024.
When did Neuronetics pay the last dividend?
The last dividend was paid out on 5/27/2024.
What was the dividend of Neuronetics in the year 2023?
In the year 2023, Neuronetics distributed 0 USD as dividends.
In which currency does Neuronetics pay out the dividend?
The dividends of Neuronetics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neuronetics
Our stock analysis for Neuronetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuronetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
